Evidence map›Paper›PMID 26925108›Full record

ArticleStem cells international2016

Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment.

Morgan T Sutton, David Fletcher, Santosh K Ghosh, Aaron Weinberg, Rolf van Heeckeren, Sukhmani Kaur, Zhina Sadeghi, Adonis Hijaz, Jane Reese, Hillard M Lazarus and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02866721 (A Phase I, Single Center, Open Label, Single Dose, Dose Escalation Study Assessing the Safety and Tolerability of AllogeneiC MEsenchymAl Stem CEll Infusion in Adults With Cystic Fibrosis-CEASE CF), which is not on this map. Cited by 95 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02866721 phase1completednot on this map

A Phase I, Single Center, Open Label, Single Dose, Dose Escalation Study Assessing the Safety and Tolerability of AllogeneiC MEsenchymAl Stem CEll Infusion in Adults With Cystic Fibrosis-CEASE CF

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2016 to 2020Enrolled14ConditionsCystic FibrosisArmsMesenchymal Stem Cells
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Mesenchymal stromal cell extracellular vesicles reduceAmerican journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  14. Article
  15. Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reducebioRxiv : the preprint server for biology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Morgan T SuttonDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA; National Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
David FletcherDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Santosh K GhoshSchool of Dentistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Aaron WeinbergSchool of Dentistry, Case Western Reserve University, Cleveland, OH 44106, USA.
Rolf van HeeckerenDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Sukhmani KaurDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Zhina SadeghiDepartment of Urology, Case Western Reserve University, Cleveland, OH 44106, USA.
Adonis HijazDepartment of Urology, Case Western Reserve University, Cleveland, OH 44106, USA.
Jane ReeseNational Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Cancer Biology, Case Western Reserve University, Cleveland, OH 44106, USA; CTSC Cell Therapy Laboratory, Case Western Reserve University, Cleveland, OH 44106, USA.
Hillard M LazarusNational Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Cancer Biology, Case Western Reserve University, Cleveland, OH 44106, USA; CTSC Cell Therapy Laboratory, Case Western Reserve University, Cleveland, OH 44106, USA.
Donald P LennonNational Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA; Skeletal Research Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Arnold I CaplanNational Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA; Skeletal Research Center, Case Western Reserve University, Cleveland, OH 44106, USA.
Tracey L BonfieldDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA; National Center of Regenerative Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) is a genetic disease in which the battle between pulmonary infection and inflammation becomes the major cause of morbidity and mortality. We have previously shown that human MSCs (hMSCs) decrease inflammation and infection in the in vivo murine model of CF. The studies in this paper focus on the specificity of the hMSC antimicrobial effectiveness using Pseudomonas aeruginosa (gram negative bacteria) and Staphylococcus aureus (gram positive bacteria). Our studies show that hMSCs secrete bioactive molecules which are antimicrobial in vitro against Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumonia, impacting the rate of bacterial growth and transition into colony forming units regardless of the pathogen. Further, we show that the hMSCs have the capacity to enhance antibiotic sensitivity, improving the capacity to kill bacteria. We present data which suggests that the antimicrobial effectiveness is associated with the capacity to slow bacterial growth and the ability of the hMSCs to secrete the antimicrobial peptide LL-37. Lastly, our studies demonstrate that the tissue origin of the hMSCs (bone marrow or adipose tissue derived), the presence of functional cystic fibrosis transmembrane conductance regulator (CFTR: human, Cftr: mouse) activity, and response to effector cytokines can impact both hMSC phenotype and antimicrobial potency and efficacy. These studies demonstrate, the unique capacity of the hMSCs to manage different pathogens and the significance of their phenotype in both the antimicrobial and antibiotic enhancing activities.

Identifiers

PMID26925108
PMCPMC4746399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.